Here's Why UnitedHealth Group (UNH) Fell More Than Broader Market

UnitedHealth Group (UNH) recently closed down 3.59%, underperforming the broader market, despite a 3.98% gain over the past month. The company faces a mixed outlook for its upcoming October 28, 2025 earnings, with Q3 EPS projected to decrease by 60.42% to $2.83, while revenue is expected to rise 12.55% to $113.48 billion; full-year estimates show similar trends. UNH currently holds a Zacks Rank #3 (Hold) and trades at a premium valuation with a Forward P/E of 22.76 and a PEG ratio of 2.38, both above industry averages, within an industry ranked in the bottom 23%.

Analysis

UnitedHealth Group (UNH) experienced a notable daily decline of 3.59% to $354.50, underperforming the broader market, which saw the S&P 500 fall 2.71%. This recent downturn contrasts with its strong performance over the past month, where UNH gained 3.98%, surpassing both the Medical sector's 2.6% and the S&P 500's 3.5% gains, indicating market sensitivity to recent developments despite prior outperformance.

The company's upcoming Q3 2025 earnings, scheduled for October 28, 2025, project a substantial 60.42% year-over-year decrease in EPS to $2.83, alongside a 12.55% revenue increase to $113.48 billion. Full-year estimates also reflect a significant EPS decline of 41.58% but a revenue growth of 12.03%. Despite these projected EPS contractions, the Zacks Consensus EPS estimate has seen a 1.13% rise over the past month, contributing to a current Zacks Rank #3 (Hold).

UNH currently trades at a premium valuation, with a Forward P/E of 22.76, notably higher than the industry average of 17.04. Its PEG ratio of 2.38 also exceeds the Medical - HMOs industry average of 1.49, suggesting higher growth expectations relative to its peers. This premium is observed within an industry (Medical - HMOs) that holds a Zacks Industry Rank of 192, placing it in the bottom 23% of all industries, implying broader sector-specific challenges.

Key Decisions for Investors

• Investors should closely monitor UnitedHealth Group's upcoming Q3 2025 earnings release on October 28, 2025, as projected significant EPS decline alongside revenue growth presents a mixed fundamental picture.
• Given UNH's premium valuation metrics (Forward P/E of 22.76 and PEG of 2.38) relative to its industry averages, investors should assess whether the projected revenue growth justifies the current price, especially within a low-ranked industry.
• Consider the recent 1.13% rise in consensus EPS estimates as a potential positive signal for near-term trends, but balance this against the broader industry's bottom-quartile ranking and the stock's recent underperformance.